Tesamorelin 10mg | Ipamorelin 3mg (13mg Peptide Blend)

Tesamorelin 10mg | Ipamorelin 3mg for Laboratory Research

This blend supplies Tesamorelin and Ipamorelin compounded together in a single 13mg lyophilised vial — 10mg Tesamorelin with 3mg Ipamorelin. Both components are compounded and tested as one product, which removes the step of combining separate vials at the bench and keeps documentation to a single certificate of analysis. Manufactured in the USA in a USP 797 compliant sterile facility.

Mechanism of Action

The two compounds act on the growth hormone axis through different receptors. Tesamorelin is a stabilised analogue of growth hormone-releasing hormone that binds the GHRH receptor on the anterior pituitary. Ipamorelin is a selective pentapeptide agonist at the growth hormone secretagogue receptor, the same receptor targeted by ghrelin. Because the two act at separate receptors, they are frequently studied together in research examining complementary signalling.

Preclinical Research

GHRH analogues and growth hormone secretagogues each carry substantial independent preclinical literature. Research interest in combining them centres on whether stimulating two distinct receptor pathways produces signalling patterns that differ from either compound alone. Ipamorelin is of particular interest for its selectivity, having been characterised as having minimal activity at other pituitary axes in preclinical work.

Research Applications

This blend is used as an investigational tool in endocrine signalling research, pituitary receptor studies and comparative protocols examining single-pathway versus dual-pathway stimulation. Supplying both compounds pre-combined removes reconstitution variance between the two components, which matters where run-to-run consistency is being measured.

Available Sizes

Peptides Source supplies this blend at 13mg total peptide (10mg Tesamorelin, 3mg Ipamorelin). Related blends are available at other ratios, and both compounds are also stocked individually for researchers who need to vary the proportion.

Protocol & Handling

Reconstitute the lyophilised powder with bacteriostatic water to the desired research concentration. Because both compounds are present in a single vial, they reconstitute together at a fixed ratio. Store the sealed vial at -20°C, keep reconstituted material refrigerated and protected from light, and avoid repeated freeze-thaw cycles.

Tesamorelin | Ipamorelin Blend Frequently Asked Questions

What is in this blend?

A single vial containing 10mg Tesamorelin and 3mg Ipamorelin — 13mg total peptide, compounded and tested together as one product.

Why supply the two compounds pre-combined?

Compounding them together fixes the ratio and removes the reconstitution variance introduced when two separate vials are combined at the bench. It also reduces documentation to a single lot-matched certificate.

How do the two compounds differ in research models?

Tesamorelin acts at the GHRH receptor; Ipamorelin acts at the growth hormone secretagogue receptor. They are studied together because they engage distinct receptor pathways.

How is this blend reconstituted and stored?

Reconstitute with bacteriostatic water to the desired research concentration. Store the sealed vial at -20°C, keep reconstituted material refrigerated, and avoid repeated freeze-thaw cycles.

Is this blend for human use?

No. It is sold strictly as a research chemical for laboratory use by qualified professionals. It is not for human or animal consumption.